Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RELIEF symptom study in polycythemia vera
2012-002318-37Phase 3Completed
- Sponsor
- Incyte
- Start
- Sep 2012
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in polycythemia vera (PV) comparing Ruxolitinib arm with Hydroxyurea arm (2 arms). Primary endpoint: Proportion of subjects with at least 50% reduction in TSS-C at Week 16. Started Sep 2012; status: completed.
02
Drugs
ruxolitinibhydroxyurea
03
Conditions
polycythemia vera (PV)
Beyond the preview
Go deeper on 2012-002318-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002318-37.